NCT02686697 (CACTIS) is a Phase 2, PHASE3 clinical trial of L-Carnosine in Schizophrenia, sponsored by Abraham Reichenberg.

Who is sponsoring NCT02686697?

NCT02686697 is sponsored by Abraham Reichenberg.

What drugs are being tested in NCT02686697?

Interventions in NCT02686697: L-Carnosine, Placebo, Cognitive Training.

What condition does NCT02686697 study?

NCT02686697 studies Schizophrenia.

Is NCT02686697 still recruiting?

NCT02686697 is currently completed. Last updated 23 August 2022.

Last reviewed 2022-08-23 · How we verify

NCT02686697: CACTIS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Carnosine and Cognitive Training in Schizophrenia

Completed Phase 2, PHASE3 Last updated 23 August 2022

What this trial tests

Phase 2, PHASE3 trial testing L-Carnosine in Schizophrenia in 60 participants. Completed in 19 July 2022.

Timeline

1 December 2015

Primary endpoint
19 July 2022

19 July 2022

Quick facts

Lead sponsor	Abraham Reichenberg
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	1 December 2015
Primary completion	19 July 2022
Estimated completion	19 July 2022
Sites	1 location across United States

Drugs / interventions tested

L-Carnosine — full drug profile →
Placebo
Cognitive Training

Conditions studied

Schizophrenia — all drugs for Schizophrenia →

Sponsor

Abraham Reichenberg

Who can join

Adults 18 to 60, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a double-blind placebo-controlled trial to evaluate the effects of the combination of a cognition enhancing drug, i.e carnosine, with cognitive training in patients with schizophrenia. All participants will receive the same cognitive training sessions and will be randomised to either carnosine or placebo for the duration of the combined treatment period (2 weeks). Before combined training and carnosine/placebo, there is a two-week carnosine/placebo only phase to examine the effects of carnosine alone on functioning without training.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02686697 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abraham Reichenberg
Last refreshed: 23 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02686697.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing